Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals

In the latest Watchlist interview, HotCopper sat down with Neurizon Therapeutics (ASX:NUZ) managing director Michael Thurn to discuss the clinical-stage biotech company’s latest NUZ-001 OLE study – and why it’s a “critical achievement.”

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

“The topline results confirm that long-term treatment with NZU-001 in the phase two treatment dose is safe and very well tolerated,” Mr Thurn said.

“What makes this milestone even more important was that the encouraging preliminary efficacy signals that we observed, despite the small number of patients. We saw consistency across a number of outcomes, including survival.

“This data suggests NUZ-001 could have a real impact with patients living with ALS.”

Mr Thurn expanded on those ideas – and plenty more – in the Watchlist interview above.

NUZ last sold at 15.5cps on Thursday.

Join the discussion. See what HotCopper users are saying about Neurizon Therapeutics Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.